Extracorporeal Life Support in Patients with Hematologic Malignancies: A Single Center Experience
The Korean Journal of Thoracic and Cardiovascular Surgery
;
: 280-286, 2016.
Artículo
en Inglés
| WPRIM
| ID: wpr-29182
ABSTRACT
BACKGROUND:
Extracorporeal life support (ECLS) in patients with hematologic malignancies is considered to have a poor prognosis. However, to date, there is only one case series reported in the literature. In this study, we compared the in-hospital survival of ECLS in patients with and without hematologic malignancies.METHODS:
We reviewed a total of 66 patients who underwent ECLS for treatment of acute respiratory failure from January 2012 to December 2014. Of these patients, 22 (32%) were diagnosed with hematologic malignancies, and 13 (59%) underwent stem cell transplantation before ECLS.RESULTS:
The in-hospital survival rate of patients with hematologic malignancies was 5% (1/22), while that of patients without malignancies was 26% (12/46). The number of platelet transfusions was significantly higher in patients with hematologic malignancies (9.69±7.55 vs. 3.12±3.42 units/day). Multivariate analysis showed that the presence of hematologic malignancies was a significant negative predictor of survival to discharge (odds ratio, 0.07; 95% confidence interval, 0.01–0.79); p=0.031).CONCLUSION:
ECLS in patients with hematologic malignancies had a lower in-hospital survival rate, compared to patients without hematologic malignancies.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Insuficiencia Respiratoria
/
Oxigenación por Membrana Extracorpórea
/
Análisis Multivariante
/
Tasa de Supervivencia
/
Transfusión de Plaquetas
/
Neoplasias Hematológicas
/
Trasplante de Células Madre
/
Hematología
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
The Korean Journal of Thoracic and Cardiovascular Surgery
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS